Scotland’s NHS can now offer givinostat to ambulant children with Duchenne muscular dystrophy, marking a step forward in care ...

Kyverna shares Phase 2 data showing single-dose CAR-T improved mobility and reduced disability in stiff person syndrome.

Miv-cel was reported to be well tolerated in the KYSA-8 trial. No high-grade cases of cytokine release syndrome or immune ...

Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; ...

Kyverna Therapeutics stock upgraded to Strong Buy after positive phase 2 results for miv-cel in SPS and MG. Read the latest ...

Kyverna Therapeutics (KYTX) announced topline data from KYSA-8, its registrational Phase 2 trial of mivocabtagene autoleucel, a fully human, ...

CLARIFICATION: A previous version of this article incorrectly stated that tenants have three days to respond after their landlord’s initial notice to vacate, or they could be evicted by default. Per ...

Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel ...